Adverse events (grades ≥3) in advanced NSCLC patients*.

*No treatment-related adverse events (grade ≥3) were observed in trials by Neninger Vinageras et al. [21] and Wu et al. [30]; serious adverse events occurred significantly less frequently in immunotherapy groups than in control groups, but no detailed data were presented in studies by Lissoni et al. [16] and Butts et al. [22].Note: Exp: experimental group; Con: control group; ND: adverse events (grades ≥3) were not described.